Our Pricing

Purchase NHS Weight Loss Injections Online Today

When you purchase NHS weight loss injections online UK through Cured Pharmacy, you access the same MHRA-licensed treatments recommended by NICE guidelines—Mounjaro, Wegovy, and Saxenda—with transparent pricing from £135.00 a free clinical assessment under 3 minutes, and discreet home delivery. Our UK-registered prescribers evaluate your eligibility for these prescription-only GLP-1 treatments, ensuring safe, regulated access to evidence-based weight management solutions.

How NHS-Approved Weight Loss Injections Work

The weight loss injections available through UK pharmacies—Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide)—are GLP-1 receptor agonists that mimic natural gut hormones to regulate appetite and blood sugar [1]. These medications slow gastric emptying, enhance satiety signals to the brain, and improve insulin sensitivity, creating multiple pathways for weight reduction.

Mounjaro represents the latest advancement as the first dual GIP/GLP-1 receptor agonist licensed by the MHRA. In the SURMOUNT-1 trial, participants achieved an average weight reduction of 22.5% over 72 weeks on the 15mg maintenance dose—the highest reported outcome in obesity pharmacotherapy to date [1]. Wegovy demonstrated average weight loss of 14.9% over 68 weeks in the STEP 1 trial, whilst Saxenda showed 8% average reduction over 56 weeks in clinical studies [2][3].

All three treatments require subcutaneous injection and work best alongside reduced-calorie diet and increased physical activity. Your UK prescriber will determine which medication suits your medical profile, considering factors like BMI, comorbidities, and previous treatment responses.

Mounjaro, Wegovy, and Saxenda: Clinical Differences

Though all three medications belong to the incretin mimetic class, their molecular structures and dosing schedules differ significantly. Mounjaro's dual-receptor mechanism targets both GIP and GLP-1 pathways, potentially explaining its superior efficacy in head-to-head comparisons [4]. Wegovy and Saxenda both target GLP-1 receptors exclusively but differ in half-life—semaglutide's longer duration allows once-weekly dosing, whilst liraglutide requires daily administration.

Mounjaro is administered once weekly via KwikPen auto-injector, starting at 2.5mg and escalating to a maximum 15mg maintenance dose. Wegovy follows a similar weekly schedule, beginning at 0.25mg and reaching 2.4mg maintenance. Saxenda requires daily injections, starting at 0.6mg and titrating to 3mg over five weeks [5].

Which Injection Suits Your Lifestyle?

Weekly injections like Mounjaro and Wegovy offer greater convenience for patients who prefer minimal treatment burden, whilst Saxenda's daily dosing provides more granular dose control for those experiencing side effects during titration. Your UK prescriber will assess your medical history, current medications, and personal preferences during the online consultation to recommend the most appropriate option. All three treatments are subject to prescriber approval and require ongoing clinical monitoring.

Purchasing Weight Loss Injections Online: The UK Legal Process

In the UK, Mounjaro, Wegovy, and Saxenda are prescription-only medicines (POMs) regulated by the MHRA. It is illegal to purchase these medications without a valid prescription from a UK-registered prescriber. Legitimate online pharmacies like Cured Pharmacy (GPhC registration 9012511) operate under the same legal framework as high-street pharmacies, requiring clinical assessment before dispensing.

The process begins with a confidential online questionnaire reviewed by a GMC-registered doctor or independent prescriber. This typically takes under 3 minutes to complete and covers your medical history, current medications, weight management goals, and contraindications. If approved, your prescription is issued electronically and dispensed by our superintendent pharmacist Tarun Kumar (GPhC 2233073), with medication dispatched in discreet packaging.

Beware of websites offering these injections without prescription or from unregistered sources—these products may be counterfeit, improperly stored, or contain incorrect active ingredients. Always verify a pharmacy's GPhC registration number on the General Pharmaceutical Council website before purchasing.

Cost of Weight Loss Injections in the UK

Pricing for weight loss injections varies based on medication type, dose strength, and supply duration. At Cured Pharmacy, Saxenda starts from £135.00 Wegovy from £135.00 and Mounjaro from £135.00 per treatment cycle. These prices reflect genuine UK-licensed medicines sourced through regulated supply chains, unlike grey-market imports that may appear cheaper but lack quality assurance.

NHS prescription of these medications remains limited to specialist weight management services in most Clinical Commissioning Groups, with strict eligibility criteria typically requiring BMI ≥35 with comorbidities or BMI ≥40. Private prescription through registered online pharmacies provides faster access for patients who meet clinical criteria but fall outside NHS commissioning guidelines.

Cured Pharmacy guarantees transparent upfront pricing—you see exact costs before completing your clinical assessment, with no hidden consultation fees or membership subscriptions. Our lowest price guarantee ensures competitive UK pricing across all weight management treatments.

Understanding Treatment Costs Over Time

Weight loss injection therapy typically requires 6-12 months of continuous treatment to achieve and maintain clinically significant results. When budgeting, consider the full treatment course rather than single-month pricing. Your prescriber may adjust dosing based on tolerance and efficacy, which can affect monthly costs. Most patients find the investment worthwhile given the average outcomes demonstrated in clinical trials, but individual results vary and depend on adherence to lifestyle modifications alongside medication.

Side Effects and Safety Considerations for Purchase NHS Weight Loss Injections Online

The most common side effects of GLP-1 receptor agonists are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, typically most pronounced during dose escalation and diminishing over 4-8 weeks [6]. In SURMOUNT-1, 81% of tirzepatide recipients experienced at least one adverse event, though most were mild to moderate and transient. Serious side effects remain rare but include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications.

These medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, due to thyroid C-cell tumour findings in rodent studies [7]. They should be used cautiously in patients with severe gastrointestinal disease, history of pancreatitis, or diabetic retinopathy. Pregnancy and breastfeeding are absolute contraindications—women of childbearing potential should use reliable contraception and discontinue treatment 2 months before planned conception.

Your online clinical assessment screens for these contraindications and drug interactions. If approved, you'll receive detailed patient information leaflets and guidance on recognising serious adverse effects requiring medical attention. Superintendent pharmacist Tarun Kumar and our clinical team remain available for medication queries throughout your treatment.

Maximising Results: Lifestyle Modifications Alongside Medication

Clinical trial outcomes reflect medication use within comprehensive lifestyle intervention programmes, not pharmacotherapy alone. STEP trial participants received counselling on 500-calorie daily deficit and 150 minutes weekly physical activity [2]. Real-world effectiveness depends heavily on implementing similar behavioural changes—medication facilitates adherence by reducing hunger and cravings, but cannot compensate for unchanged eating patterns.

Evidence-based strategies include portion control using smaller plates, protein prioritisation at each meal (targeting 1.2-1.6g per kg ideal body weight), elimination of sugar-sweetened beverages, and structured meal timing to align with medication's appetite-suppressing effects. Regular resistance training helps preserve lean muscle mass during weight loss, maintaining metabolic rate and functional capacity.

Consider working with a registered dietitian or weight management specialist for personalised guidance. Many patients find food diaries or tracking apps helpful for identifying hidden calorie sources and maintaining accountability. Your UK prescriber may recommend follow-up consultations to monitor progress and adjust treatment as needed.

Long-Term Weight Maintenance

The STEP 4 trial demonstrated that discontinuing semaglutide after 20 weeks led to regain of two-thirds of lost weight over the subsequent year [8]. This highlights that obesity is a chronic disease requiring ongoing management rather than short-term intervention. Your prescriber will discuss maintenance strategies, which may include continuing medication at lower doses, transitioning to alternative therapies, or implementing intensive lifestyle monitoring. Sustainable weight management typically requires permanent behavioural modifications supported by medical therapy as clinically appropriate.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
5. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg solution for injection in pre-filled pen. GOV.UK.
6. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078
7. European Medicines Agency. (2022). Mounjaro EPAR – Product Information. EMA/447558/2022.
8. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss medications work best alongside reduced-calorie diet and increased physical activity.